What Is CMV DNA and How Is It Detected?

CMV DNA is the genetic material of human cytomegalovirus, a large herpesvirus whose double-stranded DNA genome spans roughly 229,000 base pairs and encodes about 200 genes. Detecting that DNA in a patient’s blood, urine, saliva, or other body fluid is the primary way clinicians confirm active CMV infection and track how much virus is present. The standard tool for detection is a molecular technique called quantitative PCR, though newer approaches are expanding the options, especially in settings where speed or cost matters more than laboratory infrastructure.

The CMV Genome in Context

Human cytomegalovirus carries one of the largest genomes of any virus that infects people. The fully sequenced genome of the laboratory strain AD169 revealed a 229-kilobase-pair DNA molecule encoding roughly 200 genes, including nine gene families, numerous genes for surface proteins, and even sequences that mimic human immune-system genes.¹ That size matters for detection because it gives laboratories plenty of unique DNA targets to design tests around. Most assays zero in on short, highly conserved stretches of the CMV genome so they can reliably pick up the virus without confusing it with related herpesviruses.

CMV belongs to the herpesvirus family, which means it has a trick that complicates detection: latency. After an initial infection, the virus parks its DNA inside certain blood-cell precursors and goes quiet. During latency the virus produces very little of its standard protein machinery, but it does deploy small RNA molecules called microRNAs that manipulate the host cell’s signaling and keep conditions favorable for eventual reactivation.² When the immune system weakens, those molecular switches flip, the virus wakes up, and CMV DNA becomes detectable in the bloodstream again. This on-off cycle is why clinicians need a reliable, sensitive way to spot even small amounts of viral DNA before the virus reaches dangerous levels.

Quantitative PCR, the Workhorse Test

The most widely used method for detecting and measuring CMV DNA is quantitative real-time PCR (often abbreviated qPCR). The test works by copying a short target region of the CMV genome millions of times, tagging each new copy with a fluorescent signal. The more viral DNA in the original sample, the sooner the signal crosses a detectable threshold. This lets the laboratory report not just whether CMV is present, but how much is present, expressed as a viral load in international units per milliliter.

Clinicians caring for transplant patients rely heavily on that viral-load number. Quantitative CMV DNA testing is the standard approach for monitoring patients after organ or stem-cell transplants, where reactivation of latent CMV can cause serious illness or death.³ By tracking viral loads over time, doctors can start antiviral drugs early, a strategy called preemptive therapy, rather than waiting for symptoms to appear. A systematic review covering studies from 2013 to 2023 found that starting antivirals when viral loads reach roughly 100 to 1,000 international units per milliliter protected patients about as well across that range.⁴

PCR also replaced older methods that were slower and less sensitive. Before molecular testing became routine, laboratories relied on techniques like shell-vial culture and antigenemia assays that required growing the virus or staining infected cells under a microscope. In a head-to-head comparison with quantitative shell-vial culture in transplant recipients, PCR detected CMV an average of about four days earlier.⁵ That head start can be the difference between a manageable episode and a dangerous one.

Whole Blood Versus Plasma

One of the less obvious decisions in CMV DNA testing is what sample material to use. Most labs test either whole blood (which includes both the liquid plasma fraction and the white blood cells where CMV hides) or plasma alone. The choice is not trivial. In a study comparing paired samples from the same patients, CMV DNA was undetectable in nearly 38% of plasma samples whose whole-blood counterparts tested positive. Among samples that were positive in both materials, about 80% showed higher viral loads in whole blood.⁶

The gap between the two materials is not consistent across patient groups either. In solid-organ transplant recipients, whole-blood and plasma viral loads tend to correlate reasonably well, but in stem-cell transplant recipients the correlation falls apart.⁷ The practical takeaway for patients and doctors is simple: pick one specimen type and stick with it for every follow-up test. Switching between whole blood and plasma mid-course can make the viral load appear to jump or drop for reasons that have nothing to do with what the virus is actually doing.

The Standardization Problem

For years, CMV viral-load results from one laboratory could not be directly compared with results from another. Different labs used different PCR kits, different DNA-extraction methods, and different calibration standards, so the same patient sample could return wildly different numbers depending on where it was tested.³ This made it almost impossible to apply a universal treatment threshold across institutions.

To address this, the World Health Organization established its first International Standard for CMV in 2010, using a preparation of the Merlin virus strain assigned a defined potency of five million international units.⁸ The idea was that every commercial and in-house PCR test could be calibrated against this single reference, so results would be reported in the same currency: IU/mL. Progress has been real but incomplete. Even after calibration against the WHO standard, some assays still show noticeable disagreement when run on actual patient samples.⁹ Test-to-test variability has narrowed compared to the pre-standardization era, but it has not disappeared, which is another reason why serial monitoring should ideally be done with the same assay at the same lab.

Detecting CMV in Newborns

Congenital CMV infection, meaning infection acquired before birth, is the most common congenital viral infection worldwide. It can cause hearing loss, developmental delays, and other serious problems, yet most infected newborns look perfectly healthy at birth. Detecting CMV DNA in a baby’s saliva or urine within the first 21 days of life is the accepted method for confirming congenital infection.

Saliva-based PCR screening is attractive because collection is painless and quick. A multicenter evaluation of a commercial real-time PCR kit found near-perfect agreement with reference methods on both saliva and urine specimens, with positive agreement above 97% for both sample types.¹⁰ However, saliva screening has a specific pitfall: false-positive results linked to donor breast milk. In one large screening program, 73% of false-positive saliva tests occurred in newborns who had received donor milk, likely because pasteurization kills live virus but does not destroy all viral DNA fragments.¹¹

Because of this, many experts still consider urine PCR the gold standard for diagnosing congenital CMV. A study of newborns born to mothers with confirmed primary CMV infection found that positive saliva results, especially those with low viral loads, frequently did not match urine findings, giving saliva a positive predictive value of only 73% against urine testing.¹² In practice, screening programs that use saliva as a first-pass test typically confirm any positive result with a urine PCR before making a diagnosis.

Why Antibody Tests Are Not Enough

People sometimes wonder why a simple blood test for CMV antibodies cannot replace molecular testing. Antibody (serological) testing does have a role: IgG antibodies tell you whether someone has ever been infected, which is useful for risk-stratifying transplant donors and recipients or for prenatal screening. But antibody tests are poor at catching active infection. In pregnant women, IgM antibodies, which are supposed to flag recent or current infection, were positive in only about 10 out of 89 cases where real-time PCR confirmed CMV DNA was actually replicating.¹³ IgM can be falsely negative when abundant IgG overwhelms the assay, and it can persist for months after the acute phase, making it unreliable for timing the infection. PCR avoids all of these problems by detecting the virus’s DNA directly, regardless of what the immune system is doing.

Droplet Digital PCR

A newer refinement of molecular testing is droplet digital PCR (ddPCR). Instead of tracking a fluorescent signal in real time the way standard qPCR does, ddPCR partitions the sample into tens of thousands of tiny droplets and counts exactly how many contain a copy of the target DNA. This approach provides absolute quantification without needing a calibration curve, and it shows improved precision at higher viral loads.¹⁴

In congenital CMV, ddPCR has shown promise as more than just a diagnostic tool. A study measuring viral loads in newborn blood and urine found that babies with high CMV DNA loads at diagnosis (at or above 2,950 copies per milliliter as measured by ddPCR) were significantly more likely to show developmental delays by 36 months of age than those with lower loads.¹⁵ If confirmed in larger studies, ddPCR-based viral loads at birth could help clinicians identify which babies need closer follow-up and which are at lower risk.

Despite these advantages, retrospective analyses in transplant patients have not yet shown that ddPCR’s extra precision translates into better clinical decisions compared to standard qPCR, particularly around the treatment thresholds that matter most.¹⁴ For now, ddPCR remains more of a research and specialized-laboratory tool than a routine clinical replacement.

Loop-Mediated Isothermal Amplification

In parts of the world where PCR machines are unavailable or impractical, an alternative called LAMP (loop-mediated isothermal amplification) offers a way to detect CMV DNA without expensive thermal cycling equipment. LAMP works at a single constant temperature, which means it can run in a simple water bath or heating block. Results can be read with the naked eye: a color change indicates the presence of viral DNA.

A LAMP assay developed for newborn CMV screening detected the virus down to about 1,100 copies per microliter within 15 minutes after DNA extraction, compared to 90 minutes for conventional qPCR.¹⁶ The test showed no cross-reactivity with other herpesviruses or common pathogens.¹⁷ LAMP is less precise for quantification than qPCR, so it is best suited as a yes-or-no screening tool rather than a method for tracking viral load over time. Its value lies in making CMV detection feasible in low-resource clinics, field settings, or point-of-care scenarios where sending samples to a central laboratory would cause unacceptable delays.

Testing Beyond Blood

CMV does not limit itself to the bloodstream. The virus can actively replicate in the brain, eyes, gut, and lungs, and sometimes tissue-specific testing is the only way to make the diagnosis.

In the central nervous system, PCR on cerebrospinal fluid can confirm CMV encephalitis. Studies comparing different molecular approaches on spinal fluid have reported sensitivities above 85% and specificities in the same range.¹⁸ In pediatric cases, the presence of CMV DNA in cerebrospinal fluid has been linked to serious neurological conditions including congenital encephalopathy and seizure disorders.¹⁹ For eye disease, LAMP and PCR on tiny samples of vitreous fluid from inside the eye have been used to diagnose CMV retinitis, achieving complete concordance between the two methods in one evaluation.¹⁷

Breast milk is another body fluid where CMV DNA turns up routinely. Among mothers who are CMV-seropositive, close to half of breast milk samples can test positive for viral DNA. The viral load in milk typically rises over the first four to six weeks postpartum, peaks, and then gradually returns to baseline by about 10 to 12 weeks.²⁰ This pattern is clinically relevant for very premature infants, who may acquire postnatal CMV infection through breast milk.²¹ Pasteurization reduces infectivity, but as noted in the newborn-screening section, fragments of CMV DNA can survive the process and cause confusing test results if they end up in a baby’s saliva.

Drug Resistance Testing Through DNA Sequencing

When a transplant patient’s viral load keeps rising despite antiviral treatment, the next question is whether the virus has developed drug resistance. The answer lies in sequencing specific portions of CMV DNA. Most resistance mutations cluster in two genes: UL97, which encodes a kinase that activates the antiviral ganciclovir, and UL54, which encodes the viral DNA polymerase targeted by several drugs. A sequencing-based assay can cover the critical regions of both genes and return results within two days, with sensitivity down to about 240 IU/mL of viral DNA.²² The workflow starts the same way as any CMV DNA test, with PCR amplifying the target regions, but then goes a step further by reading the actual sequence of nucleotide bases to look for known resistance-associated changes.²³ Identifying resistance early lets doctors switch to an alternative antiviral before the infection becomes uncontrollable.

Pitfalls That Can Mislead a Test Result

Molecular testing for CMV DNA is sensitive and specific, but it is not immune to error. Two sources of trouble deserve special attention.

The first is sample handling. If blood is drawn and left sitting at room temperature before the plasma is separated, white blood cells begin to break down and release their contents, including any latent CMV DNA hiding inside. In one study of patients known to carry latent (non-active) CMV, the rate of detectable CMV DNA in plasma jumped from 10% in freshly processed samples to 37% after just four hours at room temperature.²⁴ The viral loads were low, but in a clinical setting where any positive result might trigger antiviral therapy, a false positive from sloppy sample handling could lead to unnecessary treatment with drugs that carry real side effects.

The second pitfall runs in the opposite direction: false negatives caused by antiviral drugs contaminating the PCR reaction. Laboratory work has shown that acyclovir triphosphate, the active form of a common antiviral, can inhibit the enzyme that drives PCR, preventing the reaction from amplifying CMV DNA even when it is present.²⁵ This is a niche scenario, most DNA extraction methods remove drug residues effectively, but it underscores why negative PCR results in patients receiving antiviral prophylaxis should not be taken entirely at face value without clinical context.

CMV Shedding and What Detection in Body Fluids Actually Means

Finding CMV DNA in someone’s body fluid does not always mean they are sick. Healthy people shed CMV in saliva, urine, genital secretions, and breast milk, often without knowing it. Children with congenital CMV infection shed at the highest rates, with the majority continuing to shed virus for years after birth, though prevalence drops steeply by age five. Among healthy children in group childcare settings, about one in four shed CMV at any given time, roughly double the rate of children not in group care. Healthy adults without specific risk factors shed at much lower rates, around 7% on average.²⁶

This background shedding is one reason why a positive CMV PCR result from a mucosal site like saliva or urine needs to be interpreted differently from a positive result in blood. Detecting CMV DNA in blood (viremia) almost always signals clinically relevant replication, especially in immunocompromised patients. Detecting it in urine or saliva may reflect nothing more than ordinary, low-level shedding that most healthy immune systems keep in check without any intervention at all. Context, the patient’s immune status, the specimen type, the viral load, and the clinical picture, determines what a positive CMV DNA result actually means.